Aclaris Therapeutics (ACRS) Equity Ratio (2014 - 2026)

Aclaris Therapeutics' Equity Ratio history runs 13 years deep, the most recent figure standing at 0.72 for Q1 2026.

• In Q1 2026, Equity Ratio fell 0.6% year-over-year to 0.72; the TTM figure through Mar 2026 stood at 0.72 (down 0.6% YoY), while the FY2025 annual figure was 0.64, down 9.01% from the prior year.
• Equity Ratio was 0.72 for Q1 2026 at Aclaris Therapeutics, up from 0.64 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.85 in Q2 2022 to a low of 0.64 in Q4 2025.
• Historically, Equity Ratio has averaged 0.75 across 5 years, with a median of 0.76 in 2023.
• The sharpest annual moves came in 2022 and 2025: Equity Ratio climbed 14.33% in 2022, then slipped 16.17% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.78 in 2022, then advanced by 2.58% to 0.8 in 2023, then declined by 11.33% to 0.71 in 2024, then fell by 9.01% to 0.64 in 2025, then climbed by 12.52% to 0.72 in 2026.
• The last three Equity Ratio figures came in at 0.72 (Q1 2026), 0.64 (Q4 2025), and 0.68 (Q3 2025), per Business Quant data.